🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chongqing
Clinical trial register · China

Clinical Trials in Chongqing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca99 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC38 First Affiliated Hospital of Chongqing Medical University37 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chongqing

1056 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532SCLC
DrugsTopotecan·Pumitamig·Paclitaxel
Biotheus Inc.
Phase 3
404
Binzhou, Changchun, Changsha, Chengdu, Chenzhou, Chongqing, Dalian, Foshan
2024-11-13
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-11-12
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Active, closed
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655Hemophilia A
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Recruiting
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
NCT06647862Chronic Myelomonocytic Leukemia
DrugAzacitidine
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
170
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang
2024-11-11
Recruiting
Comparison of Electrolyte Beverages and Water as Solvents for Bowel Preparation
NCT06675227Bowel Preparation Before Colonoscopy
Third Military Medical University
Not applicable
2,766
Chongqing
2024-11-11
Not yet open
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
NCT06606509Type1 Diabetes Mellitus
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Anqing, Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Quanzhou
2024-11-07
Active, closed
the Effect of Environmental Factors on Colorectal Cancer Based on Macrogenomes
NCT06852495Colon Cancer, Rectal Cancer
Dong Peng
Observational
200
Chongqing
2024-11-01
Active, closed
The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome
NCT06854146Gastric Cancers, Air Pollution
Dong Peng
Observational
200
Chongqing
2024-11-01
Recruiting
Digital Early Warning System for Acute Lung Injury in Liver Surgery
NCT07070362Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
Beijing Tsinghua Chang Gung Hospital
Observational
3,000
Beijing, Chongqing, Qingdao
2024-11-01
Recruiting
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
NCT06727669Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation
Peking University People's Hospital
Observational
3,000
Beijing, Zhengzhou, Chongqing
2024-11-01
Not yet open
Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation
NCT06604611Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Inflammation, Inflammation
DrugColchicine
Dongying Zhang
Phase 4
200
Chongqing
2024-10-31
Active, closed
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900Non-Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Cisplatin·Carboplatin
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
432
Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou
2024-10-30
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
DrugsTaxotere·Mevrometostat·Enzalutamide·Paclitaxel
Pfizer
Phase 3
600
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Active, closed
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
NCT06640049Neoplasms, Rectal
DrugDostarlimab
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273Bronchiectasis Adult
Shanghai Pulmonary Hospital, Shanghai, China
Observational
364
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning
2024-10-16
Recruiting
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
NCT06709885Colon Adenocarcinoma
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
100
Chongqing
2024-10-15
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-10-14
Active, closed
Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis
NCT06615726Ischemic Stroke, Transient Ischemic Attack
Capital Medical University
Phase 3
1,300
Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan
2024-10-10
Recruiting
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
NCT06522828Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
80
Chongqing
2024-10-10
Recruiting
Virtual Ileostomy Versus Diverting Ileostomy in Patients Undergoing Total Mesorectal Excision
NCT06633133Rectal Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not applicable
620
Chongqing
2024-10-10
Recruiting
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
NCT07515079Diabetic Macular Edema (DME)
DrugLucentis
Bio-Thera Solutions
Phase 3
406
Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi
2024-10-09
Active, closed
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT06552520Atopic Dermatitis
DrugTQH2722
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
500
Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen
2024-10-08
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Nivolumab·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
DrugTislelizumab
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Active, closed
Impact of Environmental Factors and Metabolomics on Colorectal Cancer.
NCT06643429Colorectal Cancer, Metabolic Disease
Dong Peng
Observational
700
Chongqing
2024-10-01
Active, closed
Predictive Value of Air Pollution and Metabolomics for Gastric Cancer.
NCT06641700Gastric Cancers
Dong Peng
Observational
200
Chongqing
2024-10-01
Active, closed
Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery.
NCT06645730Metabolic Syndrome
First Affiliated Hospital of Chongqing Medical University
Observational
150
Chongqing
2024-10-01
Recruiting
Brain Activation Pattern Caused by Immersive Virtual Reality Pathfinding Task in Stroke Patients: an FNIRS Study
NCT06703320Stroke, Cognitive Decline
Dingqun Bai
Observational
60
Chongqing
2024-10-01
Recruiting
Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis
NCT06422845Arteriovenous Fistula Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Recruiting
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
NCT06609447Ulcerative Colitis
DrugVedolizumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
Dyadic Sport Stacking Program for Mild Dementia and Their Family Caregivers
NCT06597981Dementia, Family Caregivers, Dyadic Intervention, Health Related Quality of Life
The University of Hong Kong
Not applicable
144
Chongqing
2024-09-19
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
Recruiting
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
NCT06783114Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
DrugsPaclitaxel-albumin·Cisplatin·Tislelizumab
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Recruiting
Statin Combined with Amlodipine Treats Primary Aldosteronism
NCT06523465Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist, Hypertension
Third Military Medical University
Phase 4
180
Chongqing
2024-09-10
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795Solid Tumor, Adult
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
Recruiting
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
NCT06512584Short Bowel Syndrome
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
72
Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xi’an
2024-09-03
Recruiting
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252Gastric Cancer
DrugsXelox·Serplulimab
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Active, closed
Milk Temperature Control and Necrotizing Enterocolitis Risk in Extremely Preterm Infants
NCT06908239Necrotizing Enterocolitis, Preterm
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not applicable
250
Chongqing
2024-09-01
Recruiting
Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring
NCT06604156Depth of Anesthesia, Nociception, Painless Gastrointestinal Endoscopy
Min Su
Observational
220
Chongqing
2024-09-01
Recruiting
Association Between Blood Pressure and Risk of PSCI
NCT06730711Stroke, Cognitive Decline, Blood Pressure
First Affiliated Hospital of Chongqing Medical University
Observational
600
Chongqing
2024-09-01
Active, closed
Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer
NCT06614660Colorectal Cancer, Imaging, Metabolomics, Prognosis
First Affiliated Hospital of Chongqing Medical University
Observational
800
Chongqing
2024-09-01
Recruiting
Analysis of Risk Factors for High Intraocular Pressure and Retinal Detachment Recurrence After Vitrectomy with Silicone Oil Tamponade in Retinal Detachment Patients
NCT06826573Rhegmatogenous Retinal Detachment
First Affiliated Hospital of Chongqing Medical University
Observational
65
Chongqing
2024-09-01
Active, closed
Clinical Efficacy and Survival Prediction Analysis of Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis
NCT07437638Liver Cirrhosis, Hepatic Encephalopathy, TIPS
The Second Affiliated Hospital of Chongqing Medical University
Observational
624
Chongqing
2024-09-01
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
DrugEmpagliflozin
Boehringer Ingelheim
Phase 3
11,000
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsSacituzumab Govitecan·Doxorubicin·Paclitaxel
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Active, closed
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977Extensive Stage Small Cell Lung Cancer
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial
NCT06569953Acute Pain, Chronic Pain, Postoperative Pain
DrugsBupivacaine hydrochloride·Liposomal bupivacaine
The Second Affiliated Hospital of Chongqing Medical University
Phase 4
284
Chongqing
2024-08-26
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Cisplatin·Carboplatin·Bevacizumab
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Active, closed
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis
NCT06700421Unresectable Locally Advanced Non-small Cell Lung Cancer
DrugsApatinib·Adebrelimab
Wei Zhou
Phase 2
32
Chongqing
2024-08-13
Recruiting
Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
NCT06635993Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Qifu Li
Observational
97
Chongqing
2024-08-12
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou
2024-08-12
Recruiting
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
NCT06279351Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Xinqiao Hospital of Chongqing
Phase 2
96
Chongqing
2024-08-11
Recruiting
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
NCT06597201End Stage Renal Disease (ESRD)
DrugAmino acid (15) peritoneal dialysis
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Active, closed
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
NCT06332014Osteoporosis
DrugProlia
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugEnlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Active, closed
A Comparative Analysis of Intertransverse Nerve Block and Paravertebral Nerve Block in Endoscopic Hepatectomy
NCT06553495Pain
Jie Chen
Not applicable
80
Chongqing
2024-08-01
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsCamizestrant·Saruparib·Anastrozole·Exemestane
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Recruiting
Biomarkers Related to PSCI: An fNIRS Study
NCT06703307Stroke, Cognitive Decline
Dingqun Bai
Observational
60
Chongqing
2024-08-01
Recruiting
68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT)
NCT06833437Primary Aldosteronism, Autonomous Cortisol Secretion
Qifu Li
Not applicable
178
Chongqing
2024-08-01
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031Crohn Disease, Stricture; Bowel, Intestinal Stricture
DrugUstekinumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
239
Beijing, Chongqing, Guangzhou, Huai'an, Suzhou, Yangzhou, Hangzhou
2024-08-01
Recruiting
Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules
NCT06423235Thyroid Nodule
Xintian Pharmaceutical
Phase 4
234
Chongqing, Xiamen, Guangzhou, Shenzhen, Shunde, Wuhan, Nanjing, Xuzhou
2024-07-30
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
NCT06351150Vasodilatory Shock
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
214
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsBevacizumab·Tislelizumab
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490Biliary Tract Cancer
DrugTQB2102
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Generalized Myasthenia Gravis
DrugTelitacicept
Vor Biopharma
Phase 3
180
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan
2024-07-17
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
DrugsBomedemstat·Hydroxyurea
Merck Sharp & Dohme LLC
Phase 3
300
Bengbu, Hefei, Beijing, Chongqing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang
2024-07-16
Recruiting
A Clinical Study of B007 in the Treatment of Pemphigus.
NCT06454357Pemphigus
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Active, closed
Efficacy and Safety of Colchicine After PCI
NCT06472908Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
DrugColchicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
8,862
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Harbin, Zhengzhou, Enshi
2024-07-09
By invitation
A Metabolomics-based Study to Explore the Mechanism of Remission of Metabolic Syndrome Radical Resection of Colorectal Cancer
NCT06710314Metabolomics
Dong Peng
Observational
150
Chongqing
2024-07-01
Active, closed
Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis
NCT06707727Myasthaenia Gravis
First Affiliated Hospital of Chongqing Medical University
Observational
100
Chongqing
2024-07-01
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Cangzhou, Shijiazhuang, Harbin
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guiyang, Shijiazhuang
2024-06-25
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing
2024-06-20
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Recruiting
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06471257Asthma
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Recruiting
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition
Children's Hospital of Chongqing Medical University
Not applicable
200
Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing
2024-06-17
Not yet open
Phase IV Study of Concomitant Administration of the sIPV and HepA
NCT06460545Polio, Hepatitis A
Institute of Medical Biology, Chinese Academy of Medical Sciences
Phase 4
2,000
Chongqing
2024-06-15
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Dexamethasone
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Active, closed
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621Triple Negative Breast Cancer(TNBC)
DrugsPumitamig·Nab-paclitaxel
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSac-TMT·Nab-paclitaxel·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Active, closed
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312Non-Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pembrolizumab
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689Peripheral Arterial Disease, Stenosis, Dissection
FrontAce Scientific Co., Ltd
Not applicable
240
Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai
2024-06-04
Not yet open
A Study on Probiotic Formula in Autistic Children
NCT06419530Autism Spectrum Disorder
Third Military Medical University
Not applicable
156
Chongqing
2024-06
Recruiting
[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients
NCT06419361Stimulator of Interferon Gene, Cancer, Positron Emission Tomography
First Affiliated Hospital of Chongqing Medical University
Phase EARLY_PHASE1
30
Chongqing
2024-05-30
Recruiting
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT06363994Mantle Cell Lymphoma
DrugsOrelabrutinib·Bendamustine·Rituximab
InnoCare Pharma Inc.
Phase 3
476
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2024-05-29
Recruiting
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
NCT06256354Cancer Surgery, Intraoperative Hypothermia, Targeted Temperature Management, Postoperative Delirium
Peking University First Hospital
Not applicable
3,992
Chizhou, Hefei, Ma’anshan, Beijing, Chongqing, Shenzhen, Shijiazhuang, Harbin
2024-05-29
Recruiting
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
NCT06507683Gastrointestinal Stromal Tumors
First Affiliated Hospital of Chongqing Medical University
Not applicable
32
Chongqing
2024-05-28
Recruiting
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
NCT06329635Aneurysmal Subarachnoid Hemorrhage, Vasospasm
DrugNicardipine
The Affiliated Hospital Of Guizhou Medical University
Not applicable
396
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Kaili
2024-05-27
Rows per page Showing 501–600 of 1056
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/chongqing?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,056 of those studies with a site in Chongqing.

How many clinical trials are recruiting in Chongqing?

589 of the 1,056 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 118 have not yet opened recruitment, 334 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.